Detect exposure to cannabinoids.
Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Gray (sodium fluoride/potassium oxalate). Also acceptable: Plain red, green (sodium heparin), lavender (EDTA), or pink (K2EDTA).
Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Separator tubes. Plasma or whole blood collected in lt. blue (sodium citrate). Specimens exposed to repeated freeze/thaw cycles. Hemolyzed specimens.
After separation from cells: Ambient: 1 week; Refrigerated: 2 weeks; Frozen: 3 years
Effective August 17, 2015
|Drugs Covered||Cutoff Concentrations|
Methodology: Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Positive cutoff: 5 ng/mL
For medical purposes only; not valid for forensic use.
The drug analyte detected in this assay, 9-carboxy THC, is a metabolite of delta-9-tetrahydrocannabinol (THC). Detection of 9-carboxy THC suggests use of, or exposure to, a product containing THC. This test cannot distinguish between prescribed or non-prescribed forms of THC, nor can it distinguish between active or passive use. The plasma half-life for 9-carboxy THC metabolite is estimated to range from 4-12 hours.
Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
80349 (Alt code: G0480)
|Component Test Code*||Component Chart Name||LOINC|
|0090671||11-Nor-9-carboxy-THC, S/P, Quant||8170-3|
- Pain Management